SYRE$96.562.43%-2.40
Spyre Therapeutics Inc (SYRE)
Date: 2026-10-30 16:00O: 96.78H: 98.96L: 94.68C: 96.56Vol: 658.5k
Spyre Therapeutics Inc stock is traded at $96.56, with a volume of 658,464. It is down -2.43% in the last 24 hours and up +8.46% over the past month. Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Previous Close:
$98.96
Open:
$96.78
24h Volume:
658,464
Relative Volume:
0.73
Market Cap:
$9.02B
Revenue:
$688.00K
Net Income/Loss:
-$168.74M
P/E Ratio:
-
EPS:
-$2.36
Net Cash Flow:
-$185.87M
1W Performance:
+6.90%
1M Performance:
+8.46%
6M Performance:
+29.70%
1Y Performance:
+298.02%
1-Day Range:
$94.68$98.96
1-Week Range:
$90.35$100.42
52-Week Range:
$21.15$110.18
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Name
Spyre Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
(617) 651-5940Address
221 CRESCENT STREET, WALTHAM, USACompare SYRE vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SYRE Spyre Therapeutics Inc | $96.56 | $9.02B | $688.00K | -$168.74M | -$185.87M | -$2.36 |
 VRTX Vertex Pharmaceuticals Inc | $558.88 | $141.65B | $12.34B | $4.34B | $3.71B | $16.87 |
 REGN Regeneron Pharmaceuticals Inc | $927.89 | $95.53B | $14.92B | $4.42B | $3.79B | $41.04 |
 MRNA Moderna Inc | $221.72 | $88.52B | $2.23B | -$3.19B | -$1.60B | -$8.15 |
 ARGX Argen X Se Adr | $892.87 | $56.15B | $4.16B | $1.29B | $734.26M | $19.58 |
 ONC Beone Medicines Ltd Adr | $370.33 | $41.89B | $5.76B | $514.49M | $1.10B | $4.48 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
Spyre Therapeutics Inc Stock (SYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Spyre Therapeutics Inc Stock (SYRE) Insider Trading
- Burrows Scott LOct 01 '26Chief Financial Officer
- Transaction
- Sale
- Cost
- $91.83
- #Shares
- 7,500
- Value ($)
- 688,756
- #Shares Total
- 79,762
- CAMERON TURTLEOct 01 '26Director
- Transaction
- Proposed Sale
- Cost
- $89.03
- #Shares
- 45,000
- Value ($)
- 4,006,350
- #Shares Total
- 0
- King-Jones HeidyOct 01 '26See Remarks
- Transaction
- Sale
- Cost
- $91.03
- #Shares
- 28,933
- Value ($)
- 2,633,902
- #Shares Total
- 2,845
- HEIDY KING-JONESOct 01 '26Officer
- Transaction
- Proposed Sale
- Cost
- $89.03
- #Shares
- 29,335
- Value ($)
- 2,611,695
- #Shares Total
- 0
- Turtle CameronOct 01 '26Chief Executive Officer
- Transaction
- Sale
- Cost
- $92.01
- #Shares
- 15,000
- Value ($)
- 1,380,105
- #Shares Total
- 537,540
- Burrows Scott LOct 01 '26Chief Financial Officer
- Transaction
- Option Exercise
- Cost
- $14.50
- #Shares
- 7,500
- Value ($)
- 108,750
- #Shares Total
- 87,262
- Burrows Scott LSep 30 '26Chief Financial Officer
- Transaction
- Option Exercise
- Cost
- $14.50
- #Shares
- 17,500
- Value ($)
- 253,750
- #Shares Total
- 97,262
- SCOTT BURROWSSep 30 '26Officer
- Transaction
- Proposed Sale
- Cost
- $89.89
- #Shares
- 17,500
- Value ($)
- 1,573,157
- #Shares Total
- 0
- Burrows Scott LSep 30 '26Chief Financial Officer
- Transaction
- Sale
- Cost
- $89.89
- #Shares
- 17,500
- Value ($)
- 1,573,075
- #Shares Total
- 79,762
- King-Jones HeidySep 02 '26See Remarks
- Transaction
- Sale
- Cost
- $90.00
- #Shares
- 400
- Value ($)
- 36,000
- #Shares Total
- 2,845
